MedTrace Logo

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-09-08

Study results available
· View outcomes & findings →

Summary

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.

Conditions

  • Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,
  • Primary Peritoneal Cancer or Endometrial Cancer
  • Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer

Interventions

DRUG

MM-121

increasing doses of MM-121 IV QW

DRUG

Paclitaxel

Paclitaxel - 80 mg/m2 IV QW

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Akos Czibere, MD, PhD · Merrimack Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-05-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01209195 on ClinicalTrials.gov